<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420264</url>
  </required_header>
  <id_info>
    <org_study_id>ThermaChoice III</org_study_id>
    <nct_id>NCT00420264</nct_id>
  </id_info>
  <brief_title>ThermaChoice III Under Local Sedation in the Office Setting</brief_title>
  <official_title>Feasibility of Using Gynecare Thermachoice III in the Office Setting Without Conscious Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Female Pelvic Medicine &amp; Urogynecology Institute of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Female Pelvic Medicine &amp; Urogynecology Institute of Michigan</source>
  <brief_summary>
    <textblock>
      Investigational study to determine if an endometrial ablation for heavy uterine bleeding, can
      be tolerated in the office setting without the use of intravenous medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A safe and effective treatment , called endometrial ablation, has been used in a hospital
      setting under general anesthesia for the treatment of heavy uterine bleeding. This study will
      evaluate if patients would tolerate the same procedure in an office setting using local
      anesthetics and common pain medication. This study will include twenty patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of Uterine Ablation in the office setting</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Heavy Uterine Bleeding</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Uterine Ablation</intervention_name>
    <description>Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heavy uterine bleeding

        Exclusion Criteria:

          -  Uterine or cervical cancer

          -  Unable to tolerate office hysteroscopy

          -  Uterine fibroid tumors that distort endometrial cavity

          -  Uterine cavity greater than 12 cm

          -  Patients with hyperplasia or premalignant changes of the endometrium

          -  Active genital or urinary tract infections

          -  Intrauterine device

          -  Pregnant or want to become pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason B Bennett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grand Valley Gynecologists, PC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grand Valley Gynecologists, PC</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <name_title>Jason B. Bennett, MD</name_title>
    <organization>Female Pelvic Medicine &amp; Urogynecology Institute of Michigan</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

